Germany is the largest medical cannabis market in Europe. Avextra competes with multinational cannabis companies including Tilray Deutschland GmbH, Canopy Growth Germany GmbH, Curaleaf International (via Four 20 Pharma), Aurora Deutschland GmbH, as well as German specialists such as DEMECAN, Cannamedical Pharma GmbH, Cansativa GmbH, SynBiotic SE, Cantourage GmbH, and STADApharm GmbH.
Avextra differentiates through vertical integration (cultivation to EU-GMP manufacturing) and pharmaceutical-grade, regulator-approved medicines rather than commodity flower.
On November 9, 2022, Avextra announced a strategic partnership with Activoris Medizintechnik and Actarmo Medical to develop an EU-compliant cannabis extract inhaler, with an initial target of achieving Medical Device Regulations approval before 2024.
Under the collaboration, Avextra is responsible for crafting the active extracts, Activoris manages the device certification process, and Actarmo handles combination-product testing. Co-CEO Dr. Bernhard Babel described the initiative as a significant milestone in Avextra's broader inhalation development strategy.
